Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003557 · ClinicalTrials.gov registry record · Phase 2

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

A Phase 2 study of Liver Cancer and Gallbladder Cancer, sponsored by University of Chicago.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target
11
Study locations

NCT00003557 is a Phase 2 study of Liver Cancer and Gallbladder Cancer that has completed, run by University of Chicago. The registered enrollment target is 16 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003557, a Phase 2 study of Liver Cancer and Gallbladder Cancer, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target
11
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer.

Conditions Studied

Liver Cancer Gallbladder Cancer Extrahepatic Bile Duct Cancer

Interventions

  • DRUG dolastatin 10

Study Locations (11)

Illinois

  • University of Illinois at Chicago - Chicago
  • University of Chicago Cancer Research Center - Chicago
  • Louis A. Weiss Memorial Hospital - Chicago
  • Cancer Care Specialists of Central Illinois, S.C. - Decatur
  • Evanston Northwestern Health Care - Evanston
  • Lutheran General Cancer Care Center - Park Ridge
  • Illinois Oncology Research Association - Peoria
  • Central Illinois Hematology Oncology Center - Springfield

Indiana

  • Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
  • Michiana Hematology/Oncology P.C. - South Bend

Texas

  • University of Texas - MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 1999-01
Est. Completion 2003-08
Phase Phase 2

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003557

The ClinicalTrials.gov registry entry for NCT00003557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which dolastatin 10 is the first listed.

NCT00003557 reports 11 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Indiana, Texas.

Frequently Asked Questions

What is clinical trial NCT00003557 about?

NCT00003557 is a clinical study titled "Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer.

What is the current status of trial NCT00003557?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 1999-01. Estimated completion is 2003-08.

What conditions does trial NCT00003557 study?

This clinical trial studies the following conditions: Liver Cancer, Gallbladder Cancer, Extrahepatic Bile Duct Cancer.

What interventions are being tested in trial NCT00003557?

The interventions under investigation include: dolastatin 10 (DRUG).

Who is sponsoring clinical trial NCT00003557?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003557 being conducted?

This trial has 11 study locations across Illinois, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Cancer

All registered trials for this condition

Gallbladder Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.